Conference Day 2
Thursday June 13, 2019


Chair’s Opening Remarks

Mary Hu
Chief Executive Officer

Discovering Novel & Lower Potency Payloads


Unveiling Complex & Novel Biotransformations of Antibody Drug Conjugates Bearing CBI Dimer Payloads
• Complex and novel biotransfromations of CBI ADCs
• Impact of biotranformations on in vitro potency, in vivo efficacy and bioanalysis of CBI ADCs
• In vitro assay for predicting CBI ADC biotransformations
• Means for modulating CBI ADC biotransformations

Dian Su
Scientist Genentech


Endeavour to Successfully Develop Efficacious & Safe Next-generation ADCs
• Rational design of ADC molecule
• iLDC: Simple and efficient continuous conjugating platform
• Outstanding homogeneity and stability
• Optimized TI
• Best-in-class / First-in-class potential for various solid tumor targeting candidates

Gang Qin
Chief Executive Officer


Morning Refreshments & Networking

Discovery & Development Stream
Chair: Tse Wen Chang, CEO, Immunwork

CMC & Regulatory Stream
Chair: Firelli Alonso, Senior Director, External Supply, Pfizer

Exploring Novel Targets & Moving Beyond HER

Delving into Analytical Considerations For CMC



Development of Innovative ADCs Targeting Solid Tumors
• Screening and identifying linker-payload pairs that are both more efficacious and safer than MCC-DM1
• These linker-payload pairs maintain these superior properties when conjugated to a variety of antibodies
• Encouraging preclinical results of novel ADCs toward a list of non-Her2 targets
Xiaomai Zhou, Vice President, Hangzhou DAC Biotech

What we Learnt from the Failed ADCs & Strategy to Make a Better One
• What we learnt from the failed ADCs
• What strategy to make a better one
• Does antibody binding affinity influence ADC fate?
• Does conjugation format affect the internalisation?
Mabplex, Speaker TBC



Exploring Novel ADC Drug Targets & Molecular Mechanisms Using An In Vitro Liver Differentiation Model
• Investigation of stem cell differentiation process might provide novel therapeutic candidates for ADC drug development
• Targeting the developmental signaling pathways might provide novel therapeutic strategy in cancer treatment
Ming Lui, Professor, Guangzhou Medical University

Addressing Limitations in Resources to Improve Preclinical Candidates
• Overcoming manufacturing resource challenges
• Learn how to set up and manage complex supply chain networks efficiently
• Simplifying processes to overcome manufacturing challenges
Lily Lei, Director & Senior Manager, TOT Biopharm


Lunch & Networking

Revealing Successful Results from Companies with Candidates in the Clinic


Assessing Phase 1 interim Data of MORAb-202, a Folate Receptor Alpha-Targeted Antibody-drug Conjugate
• MORAb-202 is the first ADC which is loaded with HALAVEN® as payload
• HALAVEN® is an approved drug which exhibits unique effects on tumor microenvironment
• The interim data of MORAb-202 Phase 1 study in Japan is to be discussed

Toshimitsu Uenaka
Head, Oncology Biologics Laboratory


Reviewing the Clinical Experience of Operating a Trial in China: MRG003
• Selection of clinical investigators and sites is critical
• IRB and HGRAC approval must be obtained prior to clinical studies
• Close communication and oversight are essential for quick enrollment

Mary Hu
Chief Executive Officer


Afternoon Refreshments & Networking

Discovering Innovative Therapeutic Approaches for ADCs


Session TBC 

Youling Wu
Chief Executive Officer


Branching Out From Traditional ADCs – Small Molecule Drug Conjugates
• 3 to 5 chelator molecules or cytotoxic drug molecules (effector elements) are prepared in bundles based on novel multi-arm linkers
• The effector bundles are conjugated to an antibody molecule or to a bundle of small molecules (a targeting bundle)
• One ADC and one SMDC conjugated with DOTA chelator bundles subjected to CMC development are to be discussed

Tse Wen Chan
Chief Executive Officer & President


Chair’s Closing Remarks

Mary Hu
Chief Executive Officer